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Abstract
• The purpose of this review was to determine if SLIT was more 
effective in treating IgE mediated grass-pollen induced 
rhinoconjunctivitis than traditional SCIT. 
• The review of literature examined research comparing treatment 
outcomes of SLIT to SCIT in individuals with IgE mediated 
grass-pollen induced rhinoconjunctivitis. 
• This information will enable one to compare treatment 
outcomes between the two therapies, best delivery method, 
safety and cost. 
Research Questions
Cost effectiveness of SCIT and SLIT
Safety of SCIT and SLIT
• Rate of one fatality per 2-2.5 million SCIT injections and one 
case of anaphylaxis per 33,300 injections or per 4160 treatment 
years (on the basis of eight injections per year). An estimated 1 
billion doses of SLIT products (regardless or formulation-drops, 
tablets, etc.) have been taken by patients since 2000. Eleven 
cases of SLIT-induced anaphylaxis equate to around one case 
per 100 million SLIT administrations or per 526,000 treatment 
years. 
• Currently the mainstay of immunotherapy for AR is SCIT. The 
long-term effect SCIT has on AR is well established. SLIT is a 
newer concept and has been developed as a more convenient 
form of immunotherapy. 
• Dranitsaris and Ellis concluded from their systematic reviews of 
double-blinded placebo controlled randomized trials evaluating 
Oralair, Grazax and SCIT in patients with grass-induced 
seasonal allergic rhinitis, that the three interventions produced 
comparable benefits with reducing AR symptoms.  There was 
not a study reported that showed significant differences between 
SCIT and SLIT in reducing symptoms of AR. 
• In a study by Aasbjerg et al., the authors concluded 15 months 
of treatment was not sufficient time to completely eradicate the 
differences in SLIT tablet treatment and SCIT
• SLIT appears to be better tolerated than SCIT and majority of 
SLIT adverse events are local reactions and occur during the 
beginning of treatment and resolve within a days or weeks 
without any medical intervention.
• Dranitsaris and Ellis recommended the use of Oralair for 
immunotherapy because of its cost savings and similar efficacy 
against SCIT and Grazax. 
• The peer review literature compared the effectiveness of treating 
allergic rhinitis (AR) with subcutaneous immunotherapy (SCIT) 
versus sublingual immunotherapy (SLIT) for allergen-induced 
rhinoconjunctivitis. 
• The findings showed that there is no clear evidence of 
effectiveness between SCIT and SLIT for reducing AR 
symptoms. SLIT has been associated with cost savings with 
comparison to SCIT. 
• The findings indicated that SLIT may be the preferred route for 
immunotherapy because of its convenience, comparable 
efficacy, safety and cost. 
• In people with IgE mediated grass-pollen induced 
rhinoconjunctivitis, does SLIT have better treatment outcomes 
than traditional SCIT?
• In people with IgE mediated grass-pollen induced 
rhinoconjunctivitis, what are the risks and costs associated with 
SCIT and SLIT?
Pathophysiology of AR and the mechanism of action of SLIT 
and SCIT
• AR caused by seasonal grass pollen exposure is characterized 
by rhinorrhea, sneezing and nasal pruritus, nasal congestion, 
and includes ocular symptoms such as red/burning and 
itchy/watery eyes.
• AR is most commonly treated with intranasal corticosteroids 
and oral antihistamines. For poor control in moderate to severe 
AR with oral antihistamines and intranasal corticosteroids, 
immunotherapy should be considered. 
• Both SCIT and SLIT increase allergen tolerance via similar 
immune mechanisms, with reorientation of allergen-specific 
CD4+ T-cell responses from a T helper 2 (Th2) to Th1 and 
regulatory T-cell profiles. Allergen exposure modifies serum 
levels of allergen specific IgE and IgG. 
Comparison in effectiveness of SLIT to SCIT in AR
• Aasbjerg et al., examined the immunological comparison of 
allergen SLIT and SCIT against grass allergy over 15 months. 
The authors concluded 15 months of treatment was not 
sufficient time to completely eradicate the differences in SLIT 
tablet treatment and SCIT. 
• A systematic review and meta-analysis was performed by 
Dranitsaris & Ellis, evaluating Oralair, Grazax and SCIT. There 
was a total of 20 placebo-controlled trial that met the inclusion 
criteria. It was found that Oralair reduced the symptoms of AR 
by approximately 0.47 units (p <0.001 on a validated symptom 
scale relative to placebo). For comparison, Grazax and SCIT 
had pooled reductions of 0.34 and 0.30, respectively. 
• Dretzke et al., conducted a systematic review of effectiveness of 
SCIT and SLIT versus placebo. A total of 17 placebo-controlled 
RCTs for SCIT and 11 SLIT were utilized in the systematic 
review. Only one randomized, double-blinded study (n=71) of 
SLIT versus SCIT was identified during the search. No study 
reported significant differences between SCIT and SLIT 
• Allergy patients most often present to primary care as a point of 
first contact.
• Primary care providers (PCPs) should have the knowledge base 
on how to select the appropriate treatment for a patient’s illness 
and should be trained to make a comprehensive assessment and to 
recognize treatment failure.
• PCPs interested in treating AR with allergen immunotherapy 
should be trained in detection and management of side effects, 
including systemic and local reactions. 
• The PCP should be able to administer immunotherapy under the 
mentorship of a trained allergist and maintain regular liaisons with 
the allergist. In collaboration with the allergist, the PCP would be 
able to jointly decide when to discontinue the therapy. 
• The decision on whether to start the patient on allergy 
immunotherapy should be made by an allergist.   
• SLIT is viewed as more convenient for the patient because they 
are able to take the tablet daily at home and does not require an 
office visit. SCIT however, requires a weekly or monthly office 
visit and requires the patient to wait 30 minutes after they 
received their injection. As with any medication that is to be taken 
at home; there is a risk of non-compliance by the patient.
• AR is a common problem affecting between 30-40% of adults 
and children.
• Uncontrolled AR is one of the most common reasons to visit a 
healthcare provider.
• In the U.S., AR is responsible for 3.5 million lost workdays and 
two million lost school days every year. 
• If there is an effective prevention of AR there can be major 
socio-economic benefits. 
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Cost per patient for first 
year of therapy
Cost per patient 
for years 2 and 3 
of therapy
Oralair $1,003 $1,983
SCIT year round $3,474 $2,852
SCIT Seasonal $1,951 $3,867
Grazax $2,171 $4,327
Discussion
